Sensei Biotherapeutics Azioni (NASDAQ: SNSE)

Ultime notizie per Sensei Biotherapeutics (NASDAQ:SNSE) Azioni

Sensei Biotherapeutics

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Tuesday.
Shares of Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) rose sharply during Monday's session after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates. Also, the company announced it increased return of capital to shareholders with plans to repurchase <a href="https://www.benzinga.com/news/earnings/24/11/41748679/emerson-electric-gains-on-q4-earnings-beat-and-fy25-growth-forecast-eyes-aspentech-buyout">approximately $2B in FY25.</a>
Net sales growth of 13% year over year to $4.62 billion, beating the consensus of $4.57 billion. Underlying sales were up 4%, and underlying orders increased by 2% in the quarter. Adjusted EPS improved 15% to $1.48, beating the consensus of $1.47.
Emerson Electric shares jumped 6.6% to $117.01 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Vimeo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) shares jumped 42.7% to $6.86 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter sales guidance above estimates.</li>
<li>Gogo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) gained 29.3% to $8.47 after the company reported better-than-expected third-quarter financial results.</li>
<li>Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) rose 29.1% to $90.14 after the company reported better-than-expected third-quarter EPS and sales.</li>
<li>Aris Water Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) gained 25.8% to $20.84 following strong quarterly results.</li>
<li>Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) gained 22.4% to $50.70 after the company reported better-than-expected third-quarter financial results and issued guidance above consensus estimates.</li>
<li>UFP Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) rose 20.7% to $335.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Lindblad Expeditions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) gained 20.6% to $11.28 after the company reported better-than-expected third-quarter financial results.</li>
<li>DXP Enterprises Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) gained 18.7% to $60.45 following strong quarterly results.</li>
<li>Century Aluminum Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) gained 17.7% to $20.66 following upbeat quarterly earnings.</li>
<li>Payoneer Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) climbed 16% to $9.88 after the company reported better-than-expected quarterly EPS and sales and raised its FY24 revenue guidance.</li>
<li>Cushman &amp; Wakefield PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) gained 13.2% to $14.88 after the company reported better-than-expected quarterly adjusted EPS results.</li>
<li>Ingredion Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) rose 12.6% to $150.97 following upbeat earnings.</li>
<li>Primoris Services Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) gained 10.5% to $71.11 following strong quarterly earnings.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) rose 9.1% to $293.34.</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) gained 8.7% to $353.91 after the company reported better-than-expected third-quarter financial results.</li>
<li>Nomura Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMR#NYSE">NMR</a>) rose 7.3% to $5.64 following second-quarter results.</li>
<li>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) gained 6.8% to $149.00 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

News

Intraday Update

Markets

Movers

Trading Ideas

ALAB

ARIS

CENX

DXPE

GOGO

INGR

LIND

PAYO

PLTR

POWL

PRIM

UFPT

VMEO

Emerson Electric Posts Better-Than-Expected Results, Joins Palantir Technologies, DXP Enterprises, Cummins, Apollo Global Management And Other Big Stocks Moving Higher On Tuesday

<h3>Gainers</h3>
<ul>
<li>ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) shares moved upwards by 27.6% to $0.67 during Tuesday's regular session. The market value of their outstanding shares is at $74.3 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lindblad Expeditions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) shares rose 21.55% to $11.37. The market value of their outstanding shares is at $617.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) stock rose 21.21% to $1.6. The market value of their outstanding shares is at $66.7 million. </li>
<li>Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) stock increased by 13.64% to $4.21. The company's market cap stands at $129.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Bowlero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) stock rose 11.51% to $11.57. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) shares increased by 10.71% to $1.35. The company's market cap stands at $8.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares decreased by 13.8% to $3.1 during Tuesday's regular session. The company's market cap stands at $30.5 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock decreased by 11.0% to $0.84. The market value of their outstanding shares is at $90.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares fell 10.02% to $1.27. The market value of their outstanding shares is at $133.2 million. </li>
<li>Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) shares decreased by 9.02% to $120.86. The company's market cap stands at $7.0 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 8.96% to $0.91. The company's market cap stands at $22.1 million. </li>
<li>Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) stock decreased by 8.19% to $87.82. The company's market cap stands at $9.7 billion. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFAM

BOWL

CNTY

HOFV

JDZG

LVLU

PRPL

TDUP

WYNN

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares moved upwards by 147.2% to $0.18 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares moved upwards by 143.67% to $0.47. The market value of their outstanding shares is at $6.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares increased by 35.16% to $2.46. The company's market cap stands at $2.6 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares moved upwards by 29.29% to $38.75. The market value of their outstanding shares is at $270.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock increased by 19.42% to $2.09. The company's market cap stands at $54.3 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 18.29% to $0.76. The market value of their outstanding shares is at $29.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares decreased by 39.9% to $0.86 during Tuesday's regular session. The company's market cap stands at $36.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 29.9% to $1.97. The market value of their outstanding shares is at $3.6 million. </li>
<li>ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) stock fell 20.49% to $4.09. The market value of their outstanding shares is at $18.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares decreased by 19.06% to $11.1. The company's market cap stands at $722.1 million. The company's, Q3 earnings came out today. </li>
<li>Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares decreased by 18.09% to $3.08. The market value of their outstanding shares is at $685.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock declined by 15.56% to $1.9. The market value of their outstanding shares is at $36.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

ATIP

BJDX

BNOX

NOTV

NUWE

SANA

SMLR

VRCA

ZVSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock moved upwards by 129.5% to $9.25 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) stock increased by 26.26% to $20.91. The market value of their outstanding shares is at $639.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agrify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares rose 24.84% to $3.92. The market value of their outstanding shares is at $5.2 million. </li>
<li>Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) stock moved upwards by 22.71% to $3.35. The company's market cap stands at $77.7 million. </li>
<li>DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) shares rose 20.64% to $61.43. The company's market cap stands at $969.9 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares increased by 17.45% to $3.23. The market value of their outstanding shares is at $48.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) shares declined by 28.5% to $10.11 during Tuesday's regular session. The market value of their outstanding shares is at $854.5 million. The company's, Q3 earnings came out yesterday. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock decreased by 23.27% to $5.18. The company's market cap stands at $155.2 million. </li>
<li>Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) shares decreased by 22.4% to $5.89. The market value of their outstanding shares is at $268.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) shares fell 21.76% to $2.41. The company's market cap stands at $83.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) shares declined by 18.12% to $51.33. The market value of their outstanding shares is at $898.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) stock declined by 15.04% to $0.25. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGFY

CVGI

EFSH

HDSN

JELD

LICY

VSTE

WLGS

ZCAR

12 Industrials Stocks Moving In Tuesday's Intraday Session

WIIM

Upstream shares are trading higher after multiple firms initiated coverage on the stock with an Overweight rating.

<h3>Gainers</h3>
<ul>
<li>Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares increased by 28.4% to $89.41 during Tuesday's regular session. The company's market cap stands at $14.0 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock moved upwards by 25.94% to $2.67. The company's market cap stands at $61.8 million. </li>
<li>8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) shares rose 25.0% to $2.9. The company's market cap stands at $372.1 million. The company's, Q2 earnings came out yesterday. </li>
<li>Brightcove (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) shares increased by 23.83% to $2.65. The company's market cap stands at $118.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares rose 22.65% to $50.79. The market value of their outstanding shares is at $113.7 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) shares increased by 22.44% to $3.35. The market value of their outstanding shares is at $306.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) stock decreased by 23.3% to $1.24 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) shares declined by 22.45% to $0.19. The company's market cap stands at $3.5 million. </li>
<li>Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) stock decreased by 20.41% to $26.47. The company's market cap stands at $767.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) stock declined by 13.01% to $29.04. The market value of their outstanding shares is at $2.8 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) stock fell 11.84% to $2.3. The company's market cap stands at $422.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) stock fell 9.0% to $0.97. The company's market cap stands at $27.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AOSL

BCOV

EGHT

IDAI

NVNI

NVTS

ORKT

PRSO

12 Information Technology Stocks Moving In Tuesday's Intraday Session

RBC Capital analyst Luca Issi maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and lowers the price target from $8 to $5.

Price Target

Analyst Ratings

EDIT

RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $5

Teradata shares are trading lower after the company reported Q3 financial results and issued Q4 adjusted EPS guidance below estimates.

PINC

Premier shares are trading higher after the company reported better-than-expected Q1 financial results.

Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) November Xbox Game Pass lineup offers a diverse selection, featuring everything from tactical RPGs to quirky simulators and <a href="https://www.benzinga.com/general/gaming">high-fidelity flight experiences.</a>
Here's what's coming to Game Pass this month, as <a href="https://news.xbox.com/en-us/2024/11/04/xbox-game-pass-november-2024-wave-1/">announced</a> in an Xbox Wire post:
<ul>
<li>Metal Slug Tactics (Cloud, Console, and PC – Nov. 5) Dive into this dynamic tactical RPG that combines the iconic run-and-gun action of the Metal Slug series with roguelite elements. Assemble your squad and conquer the battlefield in this strategic twist on a classic.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41694104/microsofts-decision-to-shut-down-arkane-austin-called-stupid-by-studio-founder">Microsoft&#8217;s Decision To Shut Down Arkane Austin Called &#8216;Stupid&#8217; By Studio Founder</a>
<ul>
<li>StarCraft: Remastered (PC – Nov. 5) Experience the legendary sci-fi real-time strategy game that set the bar for the genre. With enhanced graphics, relive the battles between the Terran, Protoss, and Zerg in this definitive version of the original StarCraft.</li>
<li>StarCraft II: Campaign Collection (PC – Nov. 5) Delve into the epic campaigns of StarCraft II, featuring immersive single-player stories and intense strategy gameplay. This collection brings together the entire StarCraft II narrative, perfect for fans and newcomers alike.</li>
<li>Go Mecha Ball (Console – Nov. 6) Engage in fast-paced, mecha-themed action as you control a ball-shaped robot on a mission. This title combines unique mechanics and challenging levels, offering a fresh take on robot combat.</li>
<li>Harold Halibut (Xbox Series X&#x7C;S – Nov. 6) Step into an underwater world crafted with stop-motion aesthetics in this narrative-driven adventure. Follow Harold, a lab assistant on a spaceship submerged in an ocean, as he unravels a heartfelt story.</li>
<li>The Rewinder (Console – Nov. 6) Inspired by Chinese folklore, this puzzle-adventure game follows the journey of a Rewinder who can manipulate memories. Help lost souls resolve their regrets in a mystical, hand-drawn world.</li>
<li>Turnip Boy Robs a Bank (Console – Nov. 6) Take control of the mischievous Turnip Boy in this quirky action-adventure, where he teams up with a mob of veggies to rob a bank. Expect humor, action, and plenty of surprises.</li>
<li>Goat Simulator Remastered (Cloud, PC, and Xbox Series X&#x7C;S – Nov. 7) The ultimate chaos simulator returns with upgraded graphics and classic DLCs. Headbutt, flip, and lick your way through a sandbox world in this redefined edition of the fan-favorite Goat Simulator.</li>
<li>Microsoft Flight Simulator 2024 (Cloud, PC, and Xbox Series X&#x7C;S – Nov. 19) Push your piloting skills to new heights in the latest installment of Microsoft Flight Simulator. Featuring a vast fleet of aircraft and the most realistic world map to date, this edition brings dynamically generated missions and the ultimate in simulation realism.</li>
</ul>
<h3 class="wp-block-heading">Games Leaving Game Pass On Nov. 15, 2024:</h3>
Be sure to wrap up your gameplay in the following titles before they leave the service:
<ul>
<li>Dicey Dungeons (Cloud, Console, and PC)</li>
<li>Dungeons 4 (Cloud, Console, and PC)</li>
<li>Goat Simulator (PC)</li>
<li>Like a Dragon: Ishin! (Cloud, Console, and PC)</li>
<li>Like a Dragon: The Man Who Erased His Name (Cloud, Console, and PC)</li>
<li>Persona 5 Tactica (Cloud, Console, and PC)</li>
<li>Somerville (Cloud, Console, and PC)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41633013/sony-adds-new-death-note-game-to-november-ps-plus">Sony Adds New Death Note Game To November PS Plus</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

MSFT

Xbox Game Pass November: Metal Slug Tactics, Flight Simulator Lead New Releases

XMTR

Xometry shares are trading higher after the company reported better-than-expected Q3 financial results.

RBC Capital analyst Daniel Perlin maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and raises the price target from $95 to $104.

RBC Capital Maintains Outperform on Fidelity National Info, Raises Price Target to $104

As Election Day 2024 unfolds, <a href="https://www.benzinga.com/topic/massachusetts">Massachusetts</a> and <a href="https://www.benzinga.com/topic/oregon">Oregon</a> are capturing national attention with pivotal ballot measures on psychedelics. Both states have the potential to reshape U.S. mental health treatment by advancing policies on substances like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, part of the &#8220;psychedelic renaissance&#8221; in mental health care. These efforts signify growing momentum behind <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapy</a> as a solution for PTSD, depression, and addiction, aiming to address urgent mental health needs.
<h3 class="wp-block-heading">Massachusetts' Question 4: Legalization And Regulation Of Psychedelics</h3>
Massachusetts voters face an important decision with Question 4, which would legalize and decriminalize psychedelics for therapeutic and personal use. If passed, it would allow licensed providers to administer substances like psilocybin and MDMA for therapy and decriminalize personal use and home cultivation of psilocybin.
This initiative marks Massachusetts&#8217; first state-level push for psychedelic reform, potentially setting a precedent for other states. However, the campaign has encountered internal disagreements, particularly around the measure's dual focus on therapeutic legalization and personal decriminalization, stirring debates on potential risks like unregulated recreational use.
<h3 class="wp-block-heading">Key Supporters And Opposition In Massachusetts</h3>
The campaign for Question 4 is backed by strong support from veterans groups and drug policy advocates. The Heroic Hearts Project, a veterans&#8217; service organization has been especially vocal. The group is promoting the measure as a critical alternative treatment for veterans suffering from PTSD and other mental health conditions. Massachusetts for Mental Health Options, the primary group <a href="https://www.benzinga.com/markets/cannabis/24/10/41320243/massachusetts-veterans-advocate-for-psilocybin-legalization-will-voters-support-them">backing the measure</a>, has received endorsements from numerous veteran advocates, who see psychedelics as a promising path to healing when traditional treatments fail.
<h3 class="wp-block-heading">Local Support</h3>
Eight<a href="https://www.benzinga.com/markets/cannabis/24/02/37158739/medford-massachusets-move-to-decriminalize-psychedelics-has-statewide-reform-implications"> Massachusetts cities</a> including Salem, Somerville and Cambridge have adopted policies deprioritizing the enforcement of laws against psychedelics. Cambridge and Somerville city councils endorsed the statewide ballot measure, signaling growing momentum for change at the local level.
Despite growing support, the measure has faced opposition. A majority of Massachusetts&#8217; Special Joint Committee on Ballot Initiatives recommended against it in May, citing concerns over its broad scope. Governor Maura Healey introduced a veterans-focused bill to study psilocybin's therapeutic potential but expressed caution about full-scale legalization. Critics say the measure's decriminalization and legalization could lead to unintended consequences, like increased recreational use or regulatory challenges. The No campaign, backed by groups like Smart Approaches to Marijuana, has raised public health concerns, urging voters to reject it.
Polls indicate that Massachusetts' electorate remains divided, with undecided voters likely to influence the final outcome. Voter turnout and public interpretation of the initiative's complexities could ultimately determine its success.
<h3 class="wp-block-heading">Oregon's Evolving Psychedelic Landscape</h3>
In Oregon, where voters approved psilocybin therapy with Measure 109 in 2020, the state is once again at the forefront of psychedelic reform. Following its landmark <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">decriminalization of all drug possession</a> under Measure 110, Oregon is considering additional measures in 2024 to further expand access to psychedelic therapies, potentially addressing a wider array of mental health conditions and setting an example for other states.
These measures demonstrate Oregon's commitment to harm reduction and therapeutic options over punitive drug policies. For advocates nationwide, Oregon's ongoing initiatives offer a potential model for expanding regulated psychedelic therapy and decriminalization.
<h3 class="wp-block-heading">Federal Influence And Psychedelic Reform Movement</h3>
As <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">state initiatives gain momentum</a>, federal policy on psychedelics remains uncertain. While the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a> has approved limited research, broader legalization and therapeutic use are still unclear. However, bipartisan support for psychedelic research is growing. With votes on Massachusetts&#8217; Question 4 and Oregon&#8217;s initiatives, 2024 could be a pivotal year, particularly for MA, which may set a precedent for expanding access to transformative mental health therapies.
Cover image made with AI

Cannabis

Government

Psychedelics

Politics

Legal

2024 Election Spotlight: Massachusetts And Oregon Tackle Psychedelics Reform

Shares of MasTec Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) continued their upward trajectory in early trading on Tuesday, after climbing last week on <a href="https://www.benzinga.com/news/24/11/41688665/amazon-posts-upbeat-results-joins-cardinal-health-waters-atlassian-charter-communications-mastec-and">the company's raised 2024 adjusted earnings guidance</a>.
Despite the recent rally, the stock has more runway. The Coral Gables, Florida-based company's Power Delivery, Clean Energy &amp; Infrastructure (CE&amp;I), and Communications segments are "turning the corner," according to Truist Securities.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af1b85e930001e6383a/jamie-cook">Analyst Jamie Cook</a> upgraded the rating for MasTec from Hold to Buy, while raising the price target from $133 to $173.
The MasTec Thesis: The company's Power Delivery, CE&amp;I, and Communications segments are poised for revenue growth and margin expansion, Cook said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
MasTec is "solidifying its positioning in utility transmission and distribution through the Henkels &amp; McCoy acquisition and in renewables through the IEA acquisition," the analyst stated. 
The company and rival Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) are both "well positioned to lead the market and grow given competitive advantages which include scale, workforce, and balance sheet," he added.
"We expect strong top line growth and margin expansion in 2025 tied to secular growth in renewables, significant funding for communications infrastructure associated with BEAD funding and MTZ's recently expanded relationship with AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), and new major project wins including the $1.5 billion high-voltage transmission project MTZ announced last quarter," Cook wrote. After facing two years of margin pressure, MasTec seems poised for margin expansion in 2025 and "has line of sight to reaching double-digit EBITDA margins over the medium term," he further said.
Price Action: Shares of MasTechad risen by 3.22% to $136.87 at the time of publication on Tuesday.
Read More: <a href="https://www.benzinga.com/news/earnings/24/09/40859294/mastec-stock-rallies-31-in-the-past-6-months-is-mtz-a-buy-right-now">MasTec Stock Rallies 31% in the Past 6 Months: Is MTZ a Buy Right Now?</a>

Analyst Color

Long Ideas

Upgrades

Infrastructure Construction Company MasTec Is Poised For Double Digit Margin Expansion, Analyst Says

Bowlero Corp shares are trading higher. JP Morgan maintained an Overweight rating on the stock.

Piper Sandler analyst Korinne Wolfmeyer reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Neutral and raises the price target from $18 to $21.

Reiteration

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Piper Sandler Reiterates Neutral on Hims & Hers Health, Raises Price Target to $21

HCKT

Hackett Group shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance above estimates. Also, Craig-Hallum raised its price target on the stock from $30 to $32.

In the current session, the stock is trading at $3.81, after a 3.81% increase. Over the past month, LexinFintech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) stock increased by 14.15%, and in the past year, by 80.20%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_0.png" alt="Past Year Chart" />

<h3>LexinFintech Holdings P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 24.2 in the Consumer Finance industry, LexinFintech Holdings Inc. has a lower P/E ratio of 5.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

A Look Into LexinFintech Holdings Inc's Price Over Earnings

Piper Sandler analyst Thomas Champion reiterates Vimeo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) with a Neutral and raises the price target from $5 to $7.

Piper Sandler Reiterates Neutral on Vimeo, Raises Price Target to $7

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 5.24% on an annualized basis producing an average annual return of 18.49%. Currently, NRG Energy has a market capitalization of $17.75 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $234.21 today based on a price of $86.00 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today

LIDR, HOOK and BCAB among mid-day movers

Sensei stock plunges 46% in wake of Phase 1 data

An update from Sensei Biotherapeutics (SNSE) is now available. Sensei Biotherapeutics, Inc. has refreshed its corporate presentation, revealing it ...

Sensei Biotherapeutics Unveils Updated Corporate Presentation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sensei Biotherapeutics (SNSE – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sensei Biotherapeutics (SNSE – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Viking Therapeutics (VKTX)

Sensei Biotherapeutics (SNSE) has shared an announcement. Dr. Jessie English has announced her resignation from the Board of Directors at Sensei Bi...

Dr. Jessie English Resigns from Sensei Biotherapeutics Board

Sensei Biotherapeutics GAAP EPS of -$0.28

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) just reported results for the second quarter of 2024.<ul><li>Sensei Biotherapeutics reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snse-stock-earnings-sensei-biotherapeutics-for-q2-of-2024/">SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024

Sensei Biotherapeutics (SNSE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White ...

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Financials and Promising Drug Trials

Sensei Biotherapeutics ( ($SNSE) ) just unveiled an announcement. Sensei Biotherapeutics, Inc. recently appointed Josiah Craver as their new princi...

Sensei Biotherapeutics Appoints New Financial Chief

AKAN

BCAB

GNLX

HOOK

ISSC

LICN

LIDR

LUCY

MRUS

NCPL

OKLO

OMER

ONMD

REGN

RNAZ

SMMT

SNSE

SWIN

TLSI

TROO

VKTX

VSTM

Press Releases

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Health Care

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Earnings

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Comments

Sensei Biotherapeutics

Notizie

Ultime notizie per Sensei Biotherapeutics (NASDAQ:SNSE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO